OSAM
BDTX icon

O'Shaughnessy Asset Management’s Black Diamond Therapeutics BDTX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$534K Buy
288,871
+106,635
+59% +$261K ﹤0.01% 1570
2026
Q1 		$388K Sell
182,236
-172,218
-49% -$410K ﹤0.01% 1653
2025
Q4 		$861K Buy
354,454
+212,015
+149% +$751K ﹤0.01% 1218
2025
Q3 		$540K Buy
+142,439
New +$417K ﹤0.01% 1441

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

O'Shaughnessy Asset Management's BDTX Position: Q2 2026 in Review

O'Shaughnessy Asset Management increased its Black Diamond Therapeutics (BDTX) stake by 59% in Q2 2026, buying an estimated $261K and bringing the position to 288,871 shares worth $534K. The position accounts for ﹤0.01% of the portfolio, ranked #1570.

O'Shaughnessy Asset Management first reported a position in BDTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $861K in Q4 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • O'Shaughnessy Asset Management held 288,871 shares of Black Diamond Therapeutics worth $534K as of Q2 2026.
  • O'Shaughnessy Asset Management bought 106,635 Black Diamond Therapeutics shares in Q2 2026, an estimated $261K.
  • Black Diamond Therapeutics made up ﹤0.01% of O'Shaughnessy Asset Management's portfolio in Q2 2026, its #1570 holding.
  • O'Shaughnessy Asset Management first reported a position in Black Diamond Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • O'Shaughnessy Asset Management's Black Diamond Therapeutics position peaked at $861K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.